USE OF HYDROGENOTROPHIC ACETOGENIC STRAINS FOR PREVENTING OR TREATING DIGESTIVE DISORDERS

• US 20100316617A1
• Filed: 04/15/2010
• Published: 12/16/2010
• Est. Priority Date: 05/11/2000
• Status: Abandoned Application

• Current Assignee: Institut National de La Recherche Agronomique
• Original Assignee: Institut National de La Recherche Agronomique
• Inventors: Renaud, Michel, Bernalier, Annick
• Application Number:
  US12/760,926
• Publication Number:
  US 20100316617A1
• Time in Patent Office: Days
• US Class Current: 424/93.41
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: Y10S 435/822 using bacteria or actinomycetales

Abstract

A method of modulating the microbial balance of the digestive ecosystem in a mammal comprising administering to a mammal in need thereof a composition comprising at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain, along with a pharmaceutical and related methods, are described.

Claims

1-19. -19. (canceled)

20. A method of modulating the microbial balance of the digestive ecosystem in a mammal comprising administering to a mammal in need thereof a composition comprising at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain.

21. The method of claim 20, wherein at least one of said nonpathogenic, hydrogenotrophic, actogenic bacterial strain is an autologous strain of said mammal.

22. The method of claim 20, wherein at least one of said nonpathogenic, hydrogenotrophic, acetogenic bacterial strain is viable in the digestive tract.

23. The method of claim 20, wherein at least one of said nonpathogenic, hydrogenotrophic, acetogenic bacterial strain belongs to the Ruminococcus, Clostridium or Streptococcus genus.

24. The method of claim 23, wherein at least one of said nonpathogenic, hydrogenotrophic, acetogenic bacterial strain belongs to the species Ruminococcus hydrogenotrophicus.

25. The method of claim 20, wherein said mammal is human.

26. The method of claim 20, wherein at least one of said nonpathogenic, hydrogenotrophic, acetogenic bacterial strain is administered in a form which allows it to be active in the colon.

27. The method of claim 20, wherein said composition is administered orally or rectally.

28. The method of claim 20, wherein at least one of said nonpathogenic, hydrogenotrophic, acetogenic bacterial strain is packaged in an anaerobic environment.

29. The method of claim 20, wherein said composition comprises at least one additive which promotes the activity of the at least one strain in the digestive environment.

30. The method of claim 20, wherein said composition also comprises a pharmaceutically acceptable carrier.

31. A pharmaceutical or food composition, comprising at least one nonpathogenic, hydrogenotrophic, acetogenic bacterial strain.

32. The composition of claim 31, wherein at least one of said nonpathogenic, hydrogenotrophic, acetogenic bacterial strain belongs to the Ruminococcus, Clostridium or Streptococcus genus.

33. The composition of claim 32, wherein at least one of said nonpathogenic, hydrogenotrophic, acetogenic bacterial strain belongs to the species Ruminococcus hydrogenotrophicus.

34. The composition of claim 33, comprising at least one additive which promotes the activity of the at least one strain in the digestive environment.

35. A method for specifically monitoring, in the digestive tract of a mammal, a nonpathogenic, hydrogenotrophic, acetogenic bacterial strain administered to said mammal as a way to modulate the microbial balance of the digestive ecosystem of said mammal, comprising the following steps:

a. defining a nucleotide sequence specific for said nonpathogenic, hydrogenotrophic, acetogenic strain,

b. contacting under hybridizing conditions said nucleic acid probe with total nucleic acid extracted from fecal flora, or with fecal bacteria from said digestive tract; and

c. detecting said hybridizing of said probe with said total nucleic acid.

36. A method for producing nonpathogenic, hydrogenotrophic, acetogenic bacterial strain comprising the following steps:

a. growing said strain on a suitable medium, under conditions of strict anaerobiosis, in the presence of a carbon-based substrate and/or of H₂/CO₂ as energy source;

b. recovering bacterial cells of said strain; and

c. packaging said bacterial cells.

37. A method for specifically monitoring, in the digestive tract of a mammal, a nonpathogenic hydrogenotrophic, acetogenic bacterial strain administered to said mammal as a way to treat or prevent gastrointestinal disorder in said mammal, comprising the following steps:

a. defining a nucleotide sequence specific for said nonpathogenic, hydrogenotrophic, acetogenic strain,

b. contacting under hybridizing conditions said nucleic acid probe with total nucleic acid extracted from fecal flora, or with fecal bacteria from said digestive tract; and

c. detecting said hybridizing of said probe with said total nucleic acid.

38. The method of claim 37, wherein said gastrointestinal disorder is irritable bowel syndrome or excessive flatulence, meteorism, bloating or abdominal pain caused by gastrointestinal functional disorders.